SUMMARY The turbidimetric responses of a strain of Escherichia coli K12 to gentamicin and tobramycin were investigated. Both agents showed antibacterial activity below the conventionally measured minimum inhibitory concentration, but exposure to such subinhibitory concentrations of either agent generated a bacterial population which was able to grow in previously inhibitory concentrations at a rate equivalent to that of the parent culture. The increase in resistance was nonspecific in that both aminoglycosides were equally affected, and was unstable on multiple passage in drug-free broth.
Gentamicin is now widely used as the treatment of choice for many serious Gram-negative infections. Tobramycin has a similar spectrum of activity to gentamicin (Benveniste and Davies, 1973; Andrews et al., 1973) but is unaffected by some of the bacterial enzymes which inactivate gentamicin. The difference between an adequate therapeutic dosage and toxic dosage of these drugs is small, especially in patients with renal failure (Noone et al., 1974; Mawer et al., 1974) . It is therefore desirable that the most efficient way of using them be established.
To gain a better understanding of the interaction between drug and bacterium we have investigated the response of a strain of Escherichia coli K12 to various concentrations of gentamicin and tobramycin by continuous turbidimetric monitoring and have attempted to assess the effect of possession of an R factor conferring resistance to gentamicin alone on the responses to gentamicin and tobramycin.
Material and methods
Escherichia coli K12 strain J53 (F-, pro-, met-; 'Present address: Public Health Laboratory, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK Received for publication 27 June 1977 Clowes and Hayes, 1968) and a derivative of this strain, J53 (RS28) carrying the R factor RS28, were kindly provided by Dr Naomi Datta.
The R factor RS28 was originally derived from a strain of Serratia marcescens and belongs to the compatibility group M, which has an unusually wide host range (Hedges et al., 1975) . RS28 confers resistance to ampicillin, streptomycin, tetracycline, chloramphenicol, and gentamicin.
Growth medium was the 'complete' medium of Greenwood and O'Grady (1973) modified by replacing the phosphate buffer by tris (hydroxymethyl) aminomethane (TRIS) in order to avoid interference with aminoglycoside activity by phosphates. The medium (CMT broth) has the following constituents per litre: glucose 5 g, casitone pancreatic digest (Difco) 10 g, yeast extract (Difco) 5 g, NaCl 5 g, TRIS buffer 6 g adjusted to pH 7-2 with HCI.
Gentamicin was obtained from British Schering Ltd, and tobramycin from Eli Lilly & Co Ltd, both as pure powders. Stock solutions were prepared in sterile distilled water from which appropriate working dilutions were made.
Minimum inhibitory concentrations (MICs) of gentamicin and tobramycin for the test strains were estimated by a conventional tube dilution method using CMT broth.
Continuous turbidimetric measurements were obtained using the 12-channel opacity monitoring system described by Mackintosh et al. (1973) . Six tubes containing 19 ml of CMT broth and 1 ml of an appropriate dilution of antibiotic or sterile distilled water (drug-free control) were seeded from an overnight broth culture to achieve an inoculum of ca 106 organisms per ml. At the end of each experiment subcultures onto solid media were made to check that growth in antibiotic was not due to contamination. Adaptation was studied by seeding a fresh series of antibiotic-containing tubes with bacteria growing in the presence of peri-MIC concentrations of antibiotic in a previous experiment.
The stability of induced resistance was tested by serial daily subculture of adapted strains in antibiotic-free CMT broth, the turbidimetric response to graded antibiotic concentrations being investigated after 1, 7, 12, 18, and 24 subcultures.
Results
The MICs of gentamicin and tobramycin for E. coli K12 J53 were 4 and 2 ,ug per ml and for J53 (RS28) were 32 and 4 ,ug per ml, respectively.
RESPONSE OF E. coli K12 J53
Continuous turbidimetric records of E. coli K12 J53 grown in the presence of gentamicin and tobramycin are shown in Fig. la (Waterworth, 1972) , but under the selective pressure of antibiotic levels approaching the MIC they quickly become the majority population. In the present study E. coli K12 J53 was easily trained to grow in concentrations of gentamicin and tobramycin close to those to which bacteria may be exposed in vivo for a large part of conventional therapeutic regimes. Although peak serum levels may exceed the level of adaptation which is easily achieved, such levels are attained only transiently. It is generally believed that strains adapted to resistance in this way are unimportant clinically owing to loss of virulence. Weinstein et al. (1971 ) demonstrated loss of virulence for mice in strains of Pseudomonas aeruginosa which had been adapted to quite high gentamicin levels. However, at this level of adaptation these strains exhibited (a phenomenon that we confirm) grossly abnormal growth characteristics. Continuous turbidimetric monitoring of E. coli K12 J53 showed that no measurable change in the rate of growth, as measured by the ability to achieve a 50% opacity level (Tso), occurred at low levels of adaptation with this organism and that slightly increased resistance was not a severe handicap since after 24 subcultures in antibiotic-free broth a population adapted to a moderate increase in resistance had not completely returned to its original fully sensitive state. An important feature of this type of resistance is that it appears to extend to other aminoglycosides (Houang and Greenwood, 1977) . It is possible that those 'coliforms' frequently isolated from superficial lesions which have a decreased sensitivity to all aminoglycosides are partially adapted strains.
The effects of an R factor (RS28) conferring resistance to gentamicin but not to tobramycin by the production of an inactivating enzyme are different from those produced by adaptation (Figs 4 and 2) . In this case delayed growth in concentrations of gentamicin that are initially inhibitory may simply reflect the time taken for the gentamicin to be enzymically inactivated. However, re-exposure of the emergent bacterial population to gentamicin revealed that adaptation was contributing to the overall effect. Furthermore, the sensitivity to tobramycin was also substantially decreased by previous exposure to gentamicin, although possession of the R factor did not itself affect the intrinsic susceptibility of the organism to tobramycin.
The demonstration that exposure of a gentamicinresistant organism to gentamicin can also decrease the susceptibility of the organism to another aminoglycoside suggests that blind therapy with one aminoglycoside may compromise the success of subsequent treatment with another, even if the infecting organism proves to be resistant to the first drug by an enzymic mechanism which does not affect the second. If these in vitro considerations are substantiated clinically, it may be that blind therapy with aminoglycosides might have to be used more circumspectly than it is at present, at least in those centres where gentamicin resistance is a problem.
